GLYCOPATH, INC

Medtech · Acquired

Glycosylation-targeted liquid biopsy assays (GlycoTyper platform) that profile N-glycans of serum and plasma glycoproteins for diagnostic biomarkers

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Medtech
Total capital
$927K
Federal grants
$927K
3 awards · 2019–2023
Rank in peer group#3 of 95
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $927K$223K$428K$275K
20192020202120222023FEDERAL ↑EQUITY ↓Cumulative $927K$223K$428K$275K

Latest events

  • Federal grantHealth and Human S · Phase I · Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis$275K
  • Federal grantHealth and Human S · Phase I · Development of the GlycoHCCTyper for the early detection of HCC$428K
  • Federal grantHealth and Human S · Phase I · Development of the GlycoFibrotyper for detection of liver fibrosis$223K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 95 peers

Line = median

Medtech · Instrument

  • Federal grants#3 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • REDIMINDS INCSimilar federal contract value in Medtech · null in contracts
  • Sharklet Technologies Inc.Similar federal contract value in Medtech · null in contracts
  • Marblehead Medical LLCSimilar federal contract value in Medtech · null in contracts
  • Brighton DevelopmentSimilar federal contract value in Medtech · null in contracts
  • CytoTronics, Inc.Similar federal contract value in Medtech · null in contracts
  • AMPA INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .